Skip to main content
. 2018 Apr 27;15(6):9917–9922. doi: 10.3892/ol.2018.8596

Figure 3.

Figure 3.

Expression of 53BP1 is associated with cisplatin chemoresistance. (A) Cell viability was assayed following treatment with an increasing concentration of cisplatin for 72 h. (B) Expression of p-Akt, Bax, Bcl-2, CDK2 and p21 in SKOV3/pLPC-53BP1 and SKOV3/pLPC-vector cells following treatment with 0, 0.4, 0.8, 1.6 µg/ml cisplatin was assessed using western blot analysis. β-actin served as a loading control. The relative expression of (C) p-Akt, (D) Bax/Bcl-2, (E) CDK2 and (F) p21 in SKOV3/pLPC-53BP1 and SKOV3/pLPC-vector cells. β-actin was a normalization control. Data were represented as the mean ± standard deviation. 53BP1, tumor protein p53 binding protein 1; p-Akt, phosphorylated protein kinase B; Bax, Bcl-2 associated X; Bcl-2, B cell lymphoma-2; CDK2, cyclin dependent kinase 2.